


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of general formula I:



wherein:

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or -C(=O)R⁷;

R³ represents C₁₋₅ fluoroalkyl, C₂₋₅ fluoroalkenyl or C₂₋₅ fluoroalkynyl;

R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, halogen, cyano, hydroxy, nitro, -NR⁸R⁹, -S(O)_xR¹⁰ or -C(=O)R¹¹;

R⁷ and R¹⁰ independently represent C₁₋₄ alkyl;

R⁸, R⁹ and R¹¹ independently represent hydrogen or C₁₋₄ alkyl; and
x represents 0, 1 or 2;

with the proviso that when R¹ represents methyl, R² represents hydrogen, R³ represents 1,1,2,2-tetrafluoroethyl and R⁴ and R⁵

represent hydrogen then R⁶ cannot be hydroxy, and with the further proviso that when R¹ represents hydrogen, R² represents hydrogen and R³ represents 3-fluoropropyl then R⁴, R⁵ and R⁶ cannot represent simultaneously fluoro;

~~and the~~ or a salts, solvates ~~and or~~ prodrugs thereof.

2. (Original) A compound according to claim 1 wherein R⁴, R⁵ and R⁶ represent hydrogen.

3. (Original) A compound according to claim 1 or 2 wherein R³ represents C₁₋₅ fluoroalkyl.

4. (Original) A compound according to claim 1 or 2 wherein R³ represents C₁₋₃ fluoroalkyl, C₂₋₃ fluoroalkenyl or C₂₋₃ fluoroalkynyl.

5. (Original) A compound according to claim 1 or 2 wherein R³ represents C₁₋₃ fluoroalkyl.

6. (Original) A compound according to claim 1 or 2 wherein R³ represents 2,2,3,3,3-pentafluoropropyl.

7. (Currently amended) A compound according to ~~any of claims 1 to 6~~ claim 1 or 2 wherein R¹ represents hydrogen.

8. (Currently amended) A compound according to ~~any of claims 1 to 7~~ claim 1 or 2 wherein R² represents hydrogen or acetyl.

9. (Currently amended) A compound according to claim 1 selected from:

methyl 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoate;


methyl 2-hydroxy-4-(2,2,2-trifluoroethoxy)benzoate;
methyl 2-hydroxy-4-(2,2,3,3-tetrafluoropropoxy)benzoate;
methyl 2-hydroxy-4-(2-fluoroethoxy)benzoate;
methyl 4-(2,2-difluoroethoxy)-2-hydroxybenzoate;
2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid;
2-hydroxy-4-(2,2,2-trifluoroethoxy)benzoic acid;
2-hydroxy-4-(2,2,3,3-tetrafluoropropoxy)benzoic acid;
2-hydroxy-4-(2-fluoroethoxy)benzoic acid;
4-(2,2-difluoroethoxy)-2-hydroxybenzoic acid;
2-acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid; and
2-acetoxy-4-(2-fluoroethoxy)benzoic acid;
~~or~~ and a salt, solvate or prodrug thereof.

10. (Currently amended) 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid ~~and the~~ or a salts, solvates ~~and~~ or prodrugs thereof.

11. (Currently amended) 2-Acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid ~~and the~~ or a salts, solvates ~~and~~ or prodrugs thereof.

12-13. (Canceled)

14. (Currently amended) A pharmaceutical composition which comprises an effective amount of a compound of formula I



I

wherein:

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or -C(=O)R⁷;

R³ represents C₁₋₅ fluoroalkyl, C₂₋₅ fluoroalkenyl or C₂₋₅ fluoroalkynyl;

R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, halogen, cyano, hydroxy, nitro, -NR⁸R⁹, -S(O)_xR¹⁰ or -C(=O)R¹¹;

R⁷ and R¹⁰ independently represent C₁₋₄ alkyl;

R⁸, R⁹ and R¹¹ independently represent hydrogen or C₁₋₄ alkyl; and

x represents 0, 1 or 2;


with the proviso that when R¹ and R² each represents hydrogen, and R³ represents 3-fluorophenyl, then R⁴, R⁵ and R⁶ simultaneously cannot represent fluoro;

or a pharmaceutically acceptable salt, solvate or prodrug thereof and one or more pharmaceutically acceptable excipients.

15. (Original) A pharmaceutical composition according to claim 14 further comprising one or more additional drugs.

16. (Original) A pharmaceutical composition according to claim 14 further comprising one or more chemotherapeutic agents.

17. (Currently amended) A product comprising a compound of formula I



I

wherein:

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or -C(=O)R⁷;

R³ represents C₁₋₅ fluoroalkyl, C₂₋₅ fluoroalkenyl or C₂₋₅ fluoroalkynyl;

R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, halogen, cyano, hydroxy, nitro, -NR⁸R⁹, -S(O)_xR¹⁰ or -C(=O)R¹¹;

R⁷ and R¹⁰ independently represent C₁₋₄ alkyl;

R⁸, R⁹ and R¹¹ independently represent hydrogen or C₁₋₄ alkyl; and

x represents 0, 1 or 2;


with the proviso that when R¹ and R² each represents hydrogen, and R³ represents 3-fluorophenyl, then R⁴, R⁵ and R⁶ simultaneously cannot represent fluoro;

or a pharmaceutically acceptable salt, solvate or prodrug thereof and one or more additional drugs, as a combined preparation for simultaneous, sequential or separate use.

18. (Original) A product according to claim 17 wherein the additional drug is a chemotherapeutic agent.

19. (Currently amended) A method of treating or preventing immune diseases which comprises administering to a subject in need thereof an effective amount of ~~Use of~~ a compound of formula

I



I

wherein:

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or -C(=O)R⁷;

R³ represents C₁₋₅ fluoroalkyl, C₂₋₅ fluoroalkenyl or C₂₋₅ fluoroalkynyl;

R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, halogen, cyano, hydroxy, nitro, -NR⁸R⁹, -S(O)_xR¹⁰ or -C(=O)R¹¹;


R⁷ and R¹⁰ independently represent C₁₋₄ alkyl;

R⁸, R⁹ and R¹¹ independently represent hydrogen or C₁₋₄ alkyl; and
x represents 0, 1 or 2;

or a pharmaceutically acceptable salt, solvate or prodrug thereof
~~for the manufacture of a medicament for the treatment or~~
~~prevention of immune diseases.~~

20. (Currently amended) A method ~~Use~~ according to claim
19 wherein the immune disease is selected from the group
consisting of psoriasis, ~~other skin diseases such as~~ atopic
dermatitis, contact dermatitis, lichen planus, dermatomyositis,
scleroderma, erythema multiforme, urticaria, ~~and~~ pemphigus,
inflammatory bowel disease, ~~including Crohn's disease and~~
~~ulcerative colitis,~~ rheumatoid arthritis, ~~and other arthritic~~
~~diseases such as~~ gouty arthritis, psoriatic arthritis, juvenile
arthritis, ~~and~~ ankylosing spondylitis, multiple sclerosis ~~and~~
~~other autoimmune neuropathies,~~ diabetes, transplant rejection,
graft-versus-host disease, lupus erythematosus, vasculitis,
Sjögren's syndrome, Guillain-Barre syndrome, glomerulonephritis,
~~respiratory diseases such as~~ allergic rhinitis, asthma, fibrosis, ~~and~~
~~and~~ chronic obstructive pulmonary disease, and neoplasias with
proliferation of immune cells.

21. (Currently amended) ~~Use of~~ A method of treating or
preventing cancer which comprises administering to a subject in
need thereof a compound of formula I



I

wherein:

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or -C(=O)R⁷;

R³ represents C₁₋₅ fluoroalkyl, C₂₋₅ fluoroalkenyl or C₂₋₅ fluoroalkynyl;

R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, halogen, cyano, hydroxy, nitro, -NR⁸R⁹, -S(O)_xR¹⁰ or -C(=O)R¹¹;


R⁷ and R¹⁰ independently represent C₁₋₄ alkyl;

R⁸, R⁹ and R¹¹ independently represent hydrogen or C₁₋₄ alkyl; and

x represents 0, 1 or 2;

or a pharmaceutically acceptable salt, solvate or prodrug thereof
~~for the manufacture of a medicament for the treatment or~~
~~prevention of cancer.~~

22. (Currently amended) Process for preparing a compound
of formula I,



I

wherein:

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or -C(=O)R⁷;

R³ represents C₁₋₅ fluoroalkyl, C₂₋₅ fluoroalkenyl or C₂₋₅ fluoroalkynyl;

R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, halogen, cyano, hydroxy, nitro, -NR⁸R⁹, -S(O)_xR¹⁰ or -C(=O)R¹¹;


R⁷ and R¹⁰ independently represent C₁₋₄ alkyl;

R⁸, R⁹ and R¹¹ independently represent hydrogen or C₁₋₄ alkyl; and

x represents 0, 1 or 2;

which comprises:


(a) reacting a phenol of formula II



II

wherein R¹, R², R⁴, R⁵ and R⁶ have the meaning described above, with an alkylating agent of formula G-R³ (III), wherein R³ has the meaning described above and G represents a leaving group; or (b) ~~converting, in one or more steps,~~ a compound of formula I into another compound of formula I; and (c) optionally, if desired, after the above steps and when R¹ and/or R² represent hydrogen, reacting a compound of formula I with a base, to obtain the corresponding addition salt.

23. (New) A compound of general formula I:



I

wherein:

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or -C(=O)R⁷;

R³ represents C₁₋₅ fluoroalkyl, C₂₋₅ fluoroalkenyl or C₂₋₅ fluoroalkynyl;

R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, halogen, cyano, hydroxy, nitro, -NR⁸R⁹, -S(O)_xR¹⁰ or -C(=O)R¹¹;

R⁷ and R¹⁰ independently represent C₁₋₄ alkyl;

R⁸, R⁹ and R¹¹ independently represent hydrogen or C₁₋₄ alkyl; and

x represents 0, 1 or 2;

with the proviso that when R¹ represents methyl, R² represents hydrogen, R³ represents 1,1,2,2-tetrafluoroethyl and R⁴ and R⁵ represent hydrogen then R⁶ cannot be hydroxy, and with the further proviso that when R¹ represents hydrogen, R² represents hydrogen and R³ represents 3-fluoropropyl then R⁴, R⁵ and R⁶ cannot represent simultaneously fluoro.

24. (New) 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid.